PAVM Dec 2024 2.500 call
| Previous Close | 0.3700 |
| Open | 0.3500 |
| Bid | 0.0000 |
| Ask | 0.4000 |
| Strike | 2.50 |
| Expire Date | 2024-12-20 |
| Day's Range | 0.3000 - 0.3700 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 37 |
PR NewswirePAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), a National Cancer Institute-Designated Comprehensive Can
PR Newswire4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the 4,000th firefighter has undergone esophageal precancer testing using Lucid's EsoGuard® Esophageal DNA test as part of a #CheckYourFoodTube Precancer Testing Event. In partnership with physicians from Mass General Brigham, Boston's Local 718 International Association of Fire Fighte
- GuruFocus.com
PAVmed Inc (PAVM) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...
Explore PAVmed Inc's strategic initiatives and financial performance, including a significant partnership with Ohio State's James Cancer Hospital and a robust Series B financing round.
